Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Abasaglar® (insulin glargin): Metaboliter

Efter injektionen metaboliseras Abasaglar till 2 aktiva metaboliter: M1 och M2. Metaboliternas in vitro-aktivitet liknar insulinets.

Metabolites of Insulin Glargine

Insulin glargine is metabolized at the carboxyl terminus of the beta chain with formation of 2 active metabolites, M1 and M2. The in vitro activity of M1 and M2 are similar to that of insulin.1

Unchanged drug and these degradation products are also present in the circulation.2

In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with increasing doses of insulin glargine.1,3

The effect on glucose metabolism after subcutaneous injection of insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable, their concentration was independent of the administered dose of insulin glargine.1,3

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35(12):2626-2630. http://dx.doi.org/10.2337/dc12-0270

Glossary

M1 = 21A-Gly-human insulin

M2 = 21A-Gly-des-30B-Thr-human insulin

Datum fӧr senaste ӧversyn 2019 M07 23


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss